Improving Purification Yields in APS Research
10 Dec 2014
Video review from Dr. Charis Pericleous, University College London, explaining the benefits of using the Amicon® Pro Purification System with her research. The research focuses on improving diagnosis and treatment of Antiphospholipid Syndrome (APS), specifically with regards to demonstrating pathogenicity in animal models of domain 1 antibody directed binding in β2 glycoprotein 1 (β2GPI), and its associated clinical manifestations. Utilising the Amicon Pro allowed for higher yields from crucial patient plasma, whilst simplifying the purification process and reducing time spent.
About the company
Merck
The Life Science business of Merck KGaA, Darmstadt, Germany, which operates as MilliporeSigma in the U.S. and Canada, has some 22,000 employees and 59 manufacturing sites worldwide, with a portfolio of more than 300,000 products focused on scientific discovery, biomanufacturing and testing services.
Related products
Request Quote for All Products
Amicon® Pro Purification System
MerckIntroducing an all-in-one centrifugal device for the protein purification workflow.Traditional protein purification is a long process with many steps and multiple devices, often resulting in protein degradation and loss. Avoid the risks associated with sample transfer and reduce hands-on time when you bind, wash, elute and/or concentrate your protein in the all-in-one Amicon® Pro purification system. No matter what your workflow, the Amicon® Pro system delivers consistent, accurate sample preparation, resulting in more reliable recovery, uncompromised purity and easier data generation.Not only does the Amicon® Pro purification system represent a game-changing improvement in general affinity purification, but it also transforms applications such as depletion of abundant proteins, protein enrichment, buffer exchange and clean-up of antibody labeling reactions.
